Tanezumab and Pain Control; Migraines, Stroke, and Lupus; Hypopituitarism and Traumatic Brain Injury; Biparietal Diameter in Newborns and Mental Development
- Submission
Tanezumab and Pain Control; Migraines, Stroke, and Lupus; Hypopituitarism and Traumatic Brain Injury; Biparietal Diameter in Newborns and Mental Development
Tanezumab is a novel medication for pain control effective in osteoarthritis, acting by inhibiting nerve growth factor. Preterm infants with reduced biparietal diameter show delayed Bayley Developmental Scores at age two years. Migraine headaches predict increased riskof stroke inpatients with SLE. A significant number of patients with traumatic brain injury and subarachnoid hemorrhage develop hypopituitarism.
Submission | July 25, 2008
